Privia Health Group, Inc. (PRVA) · Nov 5, 2026 · Earnings

Privia Health earnings beat as guidance jumps on ACO deal

Beat — Diluted EPS $0.10 vs ~$0.09 consensus; revenue $657.0M vs ~$610.7M

Privia Health’s Q3 earnings beat consensus, but the bigger signal is a broad 2026 guidance raise and a 36,000-life ACO acquisition.

Privia is expanding a physician-enablement platform built around primary-care networks and value-based reimbursement, with growth increasingly tied to attributed lives and operating leverage rather than just fee-for-service volume. Its prior 2026 setup already included raised guidance and a strategy of adding providers, entering new states, and scaling value-based care.

The quarter beat a modest published bar. Q3 revenue was $657.0 million versus a published consensus of roughly $610.7 million, while diluted GAAP EPS was $0.10 versus roughly $0.09 expected. That is a genuine earnings beat, although adjusted EPS growth was only 10.5% year over year and Adjusted EBITDA rose 6.3%, so the upside was stronger at the revenue and GAAP-profit lines than in underlying quarterly operating growth.

	Q3 2026	Q3 2025	Consensus
Revenue (Financial Highlights)	$657.0M (+13.2%)	$580.4M	~$610.7M
Diluted EPS (Income Statement)	$0.10	$0.05	~$0.09
Adjusted EBITDA (Key Metrics)	$40.6M (+6.3%)	$38.2M
Attributed Lives (Key Metrics)	1.676M (+19.2%)	1.406M
Adjusted EBITDA Margin (Key Metrics)	29.4%	30.5%

The more important signal is a broad guidance reset upward. Management moved attributed-lives guidance from 1.625–1.650 million to 1.675–1.690 million, Practice Collections to $3.900–$3.950 billion from the prior high-end target of $3.750 billion, and GAAP revenue to $2.500–$2.550 billion from $2.450 billion. Care Margin, Platform Contribution, and Adjusted EBITDA were also raised, with the new $154–$157 million EBITDA range essentially above the prior $145–$155 million range. This is not just a quarterly beat; it says the growth pipeline is arriving faster than the company expected in August.

	FY 2026 updated	Prior FY 2026 guidance
Attributed Lives (Guidance)	1.675M–1.690M	1.625M–1.650M
Practice Collections (Guidance)	$3.900B–$3.950B	$3.650B–$3.750B
GAAP Revenue (Guidance)	$2.500B–$2.550B	$2.350B–$2.450B
Care Margin (Guidance)	$535M–$540M	$515M–$530M
Platform Contribution (Guidance)	$280M–$285M	$260M–$270M
Adjusted EBITDA (Guidance)	$154M–$157M	$145M–$155M

The acquisition adds a tangible 2027 growth leg, not a 2026 earnings boost. Privia paid about $36 million in cash for American Choice Healthcare MSSP, adding more than 36,000 attributed lives across existing and new states beginning January 1, 2027. The filing explicitly says the transaction should have minimal 2026 impact but contribute positively to attributed lives and Adjusted EBITDA in 2027. 〔0〕

The trade-off is that growth remains operationally and cash-flow dependent. Privia is ending its Montana partnership in January 2027, removing 69 providers and roughly $23 million of annual Practice Collections, though management expects no material 2027 EBITDA effect. More importantly, operating cash flow was negative $19.4 million through nine months, largely because receivables absorbed cash, and the company now assumes roughly 70% EBITDA-to-free-cash-flow conversion for 2026 rather than the approximately 80% target disclosed earlier in the year. The balance sheet remains debt-free, but the cash conversion is less clean than the headline earnings growth. 〔1〕

Bottom line: This was more than an in-line quarterly update: Privia beat estimates and raised every major 2026 operating target, while securing a meaningful 2027 value-based-care expansion. The weaker cash conversion and Montana exit temper the picture, but they do not outweigh the clear acceleration in the underlying growth story.

What to watch next

American Choice Healthcare ACO launch on January 1, 2027

Original filing on SEC EDGAR

More Privia Health Group, Inc. news

Live · an AI on the whole US market

Breaking down Wall Street's information edge.

A buy-side analyst on every ticker.

It reads every public company's filing the second it drops — decoded into plain English, before it's a headline. The edge every investor deserves, not just the desks.

Trade the facts, not the FOMO.

Every event

8-Ks decoded the moment they file

Every number

Fundamentals, valuation, quality

What's next

Earnings calendar + the analyst view

scroll ↓

From filing to your screen in seconds

AllSight is the fastest.

DETECT

The moment it files

Every public company, around the clock. The AI never blinks and never takes lunch — nothing to set up.

filed 9:41:03 · decoded 9:41:19

DECODE

Plain English — never a call.

The event, the numbers, how it sits vs. expectations — in seconds. The AI decodes it; you pull the trigger.

DELIVER

On your screen, before the bell

Overnight and premarket, it's already read everything. You walk into every session with the setup — not scrambling to find it.

Understand it like a Wall Street analyst. Explained like a friend.

the raw filing — read the original on SEC.gov↗

decoded▸

AllSight · BlackBerry Q2 FY27

Revenue $163.3M vs ~$144M expected; adjusted basic EPS $0.07 vs ~$0.04 consensus — a real upside surprise.Income statement
QNX revenue +27% to $80.3M; segment EBITDA $29.0M from $20.5M. “Record performance… core automotive.”Segment — QNX
Licensing jumped to $22.1M from $6.6M — it amplified the beat, but it's less recurring than QNX, so the quality sits in QNX.Segment — Licensing
FY27 guide lifted to $616–636M rev / $141–158M EBITDA, above the prior $594–621M / $119–139M framework.Guidance
QNX growth, margins, cash and a raised outlook all beat. But licensing amplified it and Secure Comms is flat — net retention 91% from 93%.Segment — Secure Comms

Know a company all the way down.

Not just one filing. AllSight profiles every public company end to end — the numbers, the quality, the insiders, the smart money, the Street. One page, nothing missed.

Price & every insider trade, plotted
A quality score ranked against every peer
40+ valuation & profitability multiples
Where each one sits in its 5-year range
Whole-market insider flow, in real time
Which superinvestors are holding it
Analyst consensus & price target

Live · — filings read this week

AllSight gives you an edge others can't.

One scan before the open, one after the close — every filing on every ticker, already decoded. You walk into every session fully prepared.

Not investment advice · a neutral translation you can check against the original SEC filing

allsight.ai

Events/ANDE/8-K · Earnings

8-K · Item 2.02 · Earnings

The Andersons — a record Renewables quarter that beat profit expectations

Filed Aug 3, 2026ANDE · NASDAQ

AllSight readBeatPriced in▲ 1.8% since filed · reaction agrees

adj. EPS $2.15 vs ~$1.48 consensus

This filing tests whether The Andersons' sharp profit increase reflects broad operating improvement or a one-off renewable-fuels boost. It also separates strong adjusted earnings and cash generation from the quarter's legal and impairment charges.

The quarter was substantially stronger than both last year and the published earnings expectation. Adjusted EPS reached $2.15, versus $0.24 a year earlier and above the published consensus of about $1.48; reported EPS was $1.65. Adjusted EBITDA more than doubled to $140 million, while sales slipped modestly — the improvement came from margins and operating performance rather than higher revenue. Financial Highlights · Statements of Operations

Q2 ($M, exc. per-share)	Q2 2026	Q2 2025	YoY
Sales & merchandising revenue	3,097.7	3,135.9	−1%
Net income (attributable)	56.6	7.9	+48.7
Diluted EPS	1.65	0.23	+1.42
Adjusted EPS	2.15	0.24	+1.91
Adjusted EBITDA	140.3	65.2	+75.1
Agribusiness adj. pretax	20.3	16.8	+3.5
Renewables adj. pretax	88.4	9.6	+78.8
Cash from operations	487.9	299.3	+188.6
Cash from ops (pre-WC)	112.9	42.9	+70.1

Renewables drove nearly all of the upside — the operating backdrop was strong, but the result also benefited materially from tax credits. Renewables' adjusted pretax income rose to $88 million on record production, stronger ethanol margins and merchandising gains. It also received $24 million of 45Z producer tax credits, so this was not solely a repeatable plant-margin improvement; the company did cite healthy export and domestic ethanol demand as supportive. Renewables — Record Q2 · Segment Data

Agribusiness improved, but it was a supporting contributor rather than the main earnings engine. Adjusted pretax income increased to $20 million as fertilizer margins improved and merchandising benefited from commodity-price volatility, despite lower fertilizer volumes. Agribusiness — Improved Q2 · Segment Data

Cash generation improved and funding capacity is comfortable, while reported earnings still absorbed meaningful non-core costs. Operating cash flow was $488 million ($113 million before working-capital changes); capital spending was $76 million. Adjusted EPS excludes $0.50 of legal-settlement, impairment and transaction items, so the $2.15 adjusted result runs ahead of the $1.65 reported. Leverage stays below the <2.5× debt-to-EBITDA target; no new quantified full-year outlook was given. Cash & Liquidity · Adjusted Net Income

Community sentiment · 612 votes

58% bullish

Bull 58%Neu 27%Bear 15%

AllSight

AllSight Pro

A buy-side analyst on every ticker — reading the whole market the second it moves.

It reads every public company's filing the instant it drops and hands you what it means — in plain English, before it's a headline.

The read itself

Not another feed. A buy-side analyst that never sleeps, on everything.

Whole-market breadthevery public company

Not the 20 names CNBC repeats. Every ticker that files — thousands of companies, one AI reading all of them.

Filed-to-decoded in secondsspeed

Filed 9:41:03, decoded 9:41:19. You've got the catalyst while the tape is still moving and the crowd's still on the headline.

Past the headlinedepth

What actually happened, the numbers that matter, how it sits vs what the Street expected, and what it sets up next.

Source-grounded & neutralrigor

Every read traces to the words in the actual filing — click to see them. A translation you can check, never a buy/sell call.

Zero effort to youconvenience

Plain English, one glance. Follow your stocks and the moment any of them files, it's in your pocket — no watching, no digging.

All of it, livePro

Free reads every session once it closes. Pro reads it the moment it files: the whole market, all day, every day.

And then — go deeper

From "what happened" to "is it worth it."

Cheap or dear?Where it trades vs its own valuation history.

The quality score, in fullAll five dimensions, ranked against its sector.

Structure & multi-year trendsRevenue, margins, cash — the hard numbers, decoded.

Insider activityWho inside the company is buying and selling.

Analyst price targetsWhere Wall Street says every name is headed.

The whole company, one pagePrice, ownership, the full read — on any ticker.

Hire your personal buy-side analyst.

Trade one usual slippage for a whole market's rhythm.

Free

forever

Every closed session, on the whole market. The live session and the deep company read stay Pro.

Monthly

$29/mo

billed monthly

Everything, live — every session the moment it files, plus the full company read. Flexible, month to month.

Best value · save 40%

Annual

$17.40/mo

$209 billed yearly

about one slippage a month

Same full access — the whole market live and every company — at the lowest price. 40% off the monthly.

Billed today. Powered by Stripe · AllSight never sees your card.

Privia Health earnings beat as guidance jumps on ACO deal

What to watch next

More Privia Health Group, Inc. news

Breaking down Wall Street's information edge.